Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Therapeutics and Clinical Risk Management

Volumn 4, Issue 4, 2008, Pages 821-826

  Savica, Vincenzo ^a,b   Santoro, Domenico ^a   Monardo, Paolo ^b   Mallamace, Agostino ^a   Bellinghieri, Guido ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Papardo Hospital   (Italy)

Author keywords

Chronic kidney disease; Hemodialysis; Hyperphosphatemia; Sevelamer carbonate

Indexed keywords

ATORVASTATIN; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CARBONIC ACID; LANTHANUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; PHOSPHORUS; RENVELA; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; BICARBONATE BLOOD LEVEL; CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR CALCIFICATION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIET RESTRICTION; DISEASE EXACERBATION; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; INFLAMMATION; LIPID METABOLISM; LIVER TOXICITY; LUNG TOXICITY; MALNUTRITION; METABOLIC ACIDOSIS; MINERAL METABOLISM; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; PATIENT COMPLIANCE; PERITONITIS; PHOSPHATE BLOOD LEVEL; REVIEW; ULCER;

EID: 52949110171     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Almirall Daly J, Valenzuela MP. 2006. The safety of phosphate binders. Expert Opin Drug Saf, 5:675-86.
2. Block GA, Hulbert-Shearon TE, Levin NW, et al. 1998. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis, 31:607-17.
3. Block GA, Raggi P, Bellasi A, et al. 2007. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int, 71:438-41.
4. Cozzolino M, Galassi A, Pasho S, et al. 2008. Preventive measures and new pharmacological approaches of calcium and phosphate disorders. Contrib Nephrol, 161:234-9.
5. De Santo NG, Frangiosa A, Anastasio P, et al. 2006. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol, 19(S9):S108-14.
6. Delmez J, Block G, Robertson J, et al. 2007. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol, 68:386-91.
7. Drüeke TB, 2007. Lanthanum carbonate as a first-line phosphate binder: the "cons". Semin Dial, 20:329-32.
8. Duggal A, Hanus M, Zhorov E, et al. 2006. Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr, 16:248-52.
9. EMEA. 2007. Scientific discussion on Renagel. Procedure EMEA/H/C000254/ II/56, 1 June 2007.
10. Ganesh SK, Stack AG, Levin NW et al. 2001. Association of elevated serum PO4, Ca × PO4 product, and paratyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol, 12:2131-8.
11. Giachelli CM. 2003. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14:S300-4.
12. Hamer RA, El Nahas M. 2006. The burden of chronic kidney disease. BMJ, 332:563-4.
13. Kalantar-Zadeh K, Mehrotra R, Fouque D, et al. 2004. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial, 17:455-65.
14. Kawagishi T, Nishizawa Y, Konishi T, et al. 1995. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int, 48:820-6.
15. Kestenbaum B, Sampson JN, Rudser KD, et al. 2005. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol, 16:520-8.
16. Ketteler M, Rix M, Fan S, et al. 2008. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol, doi 10.2215/CJN.05161107.
17. Kraut JA. 1995. The role of metabolic acidosis in the pathogenesis of renal osteodystrophy. Adv Ren Replace Ther, 2:40-51.
18. Lacour B, Lucas A, Auchere D, et al. 2005. Chronic renal failure is associated with increase tissue deposition of lanthanum after 28-day oral administration. Kidney Int, 67:1062-69.
19. Lacour B, Nikolov IG, Joki N. 2007. Lanthanum carbonate, body lanthanum accumulation and potential liver toxicity. Nephrol Dial Transplant, 22:1788-99.
20. Li X, Yang HY, Giachelli CM. 2006. Role of sodium-dependent phosphate co-transporter, Pit-1, in vascular smooth cell calcification. Circ Res, 98:905-12.
21. Madan P, Bhayana S, Chandra P, et al. 2008. Lower gastrointestinal bleeding: association with sevelamer use. World J Gastroenterol, 14:2615-6.
22. Mathew S, Tustison KS, Sugatani T, et al. 2008. The mechanism of phopshorus as a cardiovascular risk factor in CKD. JASN, doi:10.1681/ASN.20070707060.
23. McIntyre CW. 2007. New developments in the management of hyperphosphatemia in chronic kidney disease. Semin Dial, 20:337-41.
24. Qunibi WY. 2007. Cardiovascular calcification in nondialyzed patients with chronic kidney disease. Semin Dial, 20:134-8
25. Qunibi W, Moustafa M, Muenz LR, et al. CARE-2 Investigators. 2008. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. Am J Kidney Dis, 51:952-65.
26. Russo D, Miranda I, Ruocco C, et al. 2007. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int, 72:1255-61.
27. Sigrist MK, Taal MW, Bungay P, et al. 2007. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol, 2:1241-8.
28. St. Peter WL, Liu J, Weinhandl E, et al. 2008. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the dialysis clinical outcomes revisited (DCOR) randomized trial using claims data. Am J Kidney Dis, 51:445-54.
29. Suki WN. 2008. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr, 18:91-8.
30. Szeto CC, Wong TY, Chow KM, et al. 2003. Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialys patients: a randomized placebo-control trial. J Am Soc Nephrol, 14:2119-26.
31. Toussaint ND, Kerr PG. 2007. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology, 12:500-9.
32. Winkelmayer WC, Tonelli M. 2008. Phosphate binder choice in dialysis patients: a call for evidence.based rather than marketing-based clinical practice. Am J Kidney Dis, 51:362-5.
33. Young EW, Albert JM, Satayathum S e al. 2005. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int, 67:1179-87.
34. Young EW. 2007. Mineral metabolism and mortality in patients with chronic kidney disease. Adv Chronic Kidney Dis, 14:13-21.